ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)
ARCH Venture Fund X, L.P. purchased 1,200,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).
How this was made
The 30-second read
Why it matters
The $18M purchase by a 10% owner is a material event for Aspen Neuroscience, likely influencing short‑term price dynamics.
Market read
Insider buying at this scale is a notable catalyst for a micro‑cap biotech, offering a potential trade signal.
What to watch
Potential upcoming clinical trial data or regulatory events not disclosed could be the real driver behind the purchase.
Background
Form 4 filings provide primary‑source disclosure of insider transactions, offering fresh data for traders.
Ticker impact
ARCH Venture Fund X, L.P. purchased 1.2M shares of Aspen Neuroscience at $15 each, a $18M insider buy disclosed via Form 4.
likely upward pressure as the market prices in the insider confidence
A 10% owner buying $18M of stock is material for a micro‑cap, indicating strong insider belief in near‑term prospects.
Market effects
May boost sentiment in the biotech sector as insider confidence can be seen as a positive signal.
Limited to U.S. markets; no broader regional effect.
Minimal global impact beyond investors tracking micro‑cap biotech stocks.
Counterpoint
The purchase could be a strategic stake without implying near‑term upside; price may already reflect the news.
Key entities
- companyAspen Neuroscience, Inc.
Biotech firm whose stock was purchased.
- investment_fundARCH Venture Fund X, L.P.
Insider buyer acquiring a 10% stake.
